We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$345M
AUM Growth
+$3.48M
Cap. Flow
-$46.4M
Cap. Flow %
-13.44%
Top 10 Hldgs %
30.53%
Holding
110
New
11
Increased
34
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$13.9M
2
CELG
Celgene Corp
CELG
+$10.8M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.32M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.74M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.4M

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$10.3M
2
MDT icon
Medtronic
MDT
+$6.86M
3
ALKS icon
Alkermes
ALKS
+$6.27M
4
INCY icon
Incyte
INCY
+$4.12M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$4.03M

Sector Composition

Rank Sector Weight
1 Healthcare 80.57%
2 Consumer Staples 1.97%
3 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$126B
$4.51M 1.31%
38,000
-5,000
-12% -$563K
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$4.51M 1.31%
368,000
+168,000
+84% +$2.05M
SLXP
28
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$4.37M 1.27%
38,000
-16,000
-30% -$1.94M
EIGR
29
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.83M 1.11%
436
-134
-24% -$778K
NKTR icon
30
Nektar Therapeutics
NKTR
$2.58B
$3.69M 1.07%
15,867
-18,000
-53% -$3.85M
COR icon
31
Cencora
COR
$61.2B
$3.61M 1.05%
40,000
-10,000
-20% -$858K
DXCM icon
32
DexCom
DXCM
$32B
$3.52M 1.02%
256,000
-168,000
-40% -$2.06M
CYH icon
33
Community Health Systems
CYH
$423M
$3.45M 1%
77,440
-18,150
-19% -$776K
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.43M 0.99%
22,000
+3,400
+18% +$628K
MCK icon
35
McKesson
MCK
$101B
$3.32M 0.96%
16,000
-6,000
-27% -$1.22M
INCY icon
36
Incyte
INCY
$24.4B
$3.22M 0.93%
44,000
-63,000
-59% -$4.12M
CLDX icon
37
Celldex Therapeutics
CLDX
$3.28B
$3.19M 0.93%
11,667
+2,467
+27% +$613K
NPSP
38
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$3.18M 0.92%
89,000
-135,000
-60% -$4.03M
HCA icon
39
HCA Healthcare
HCA
$89.5B
$3.01M 0.87%
41,000
-17,000
-29% -$1.19M
THOR
40
DELISTED
THORATEC CORPORATION
THOR
$2.99M 0.87%
92,000
-41,800
-31% -$1.22M
ELGX
41
DELISTED
Endologix Inc
ELGX
$2.97M 0.86%
19,400
-600
-3% -$74.9K
CNC icon
42
Centene
CNC
$32.5B
$2.91M 0.84%
112,000
-8,000
-7% -$187K
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$16.7B
$2.85M 0.83%
17,400
+7,400
+74% +$1.23M
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.82M 0.82%
159,854
+10,854
+7% +$170K
CPHD
45
DELISTED
Cepheid Inc
CPHD
$2.81M 0.82%
52,000
+7,000
+16% +$354K
BDX icon
46
Becton Dickinson
BDX
$48.2B
$2.8M 0.81%
+20,646
New +$2.64M
HTWR
47
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$2.79M 0.81%
+38,000
New +$2.89M
ABMD
48
DELISTED
Abiomed Inc
ABMD
$2.78M 0.81%
73,000
-47,736
-40% -$1.51M
TMO icon
49
Thermo Fisher Scientific
TMO
$220B
$2.76M 0.8%
22,000
-27,000
-55% -$3.28M
ARIA
50
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.73M 0.79%
397,000
-26,000
-6% -$163K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rhenman & Partners Asset Management held 110 positions worth $345M, up 1% from $342M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $46.4M in Q4 2014, closing 26 positions and reducing 36 holdings. Its most notable exit was Universal Health Services, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in RECEPTOS INC COM STK (DE) worth $6.43M.

  • Rhenman & Partners Asset Management's largest Q4 2014 buy was RECEPTOS INC COM STK (DE): 52,526 shares worth $6.43M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2014, an estimated $13.9M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2014 reduction was Medtronic, cutting an estimated $6.86M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q4 2014, selling an estimated $10.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $345M portfolio in Q4 2014.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 26 in Q4 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1% quarter-over-quarter to $345M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.